Additionally, PRMT5 inhibitors JNJ-64619178 and GSK3326595 are currently in phase I clinical trials (ClinicalTrials.gov identifier numbers NCT03573310 and NCT03614728, respectively) for patients with advanced cancers. The gene discussed is PRMT5; the disease is cancer.